the PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators +16 more
openalex +2 more sources
Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B. [PDF]
Castellana E, Chiappetta MR.
europepmc +1 more source
Review of \u3cem\u3eThe X in Sex,\u3c/em\u3e by David Bainbridge [PDF]
Lysaught, M. Therese
core +1 more source
The unforeseen consequence of smart bio-implants for hemophilia: chronic inflammation and antibody development. [PDF]
Ali FZ +4 more
europepmc +1 more source
Efficacy, quality of life, and safety of non-clotting factor prophylaxis in Hemophilia A and b: A meta-analysis across inhibitor status [PDF]
Abdul basit Khan +11 more
openalex +1 more source
Gene transfer to hemophilia A mice via oral delivery of FVIII–chitosan nanoparticles
Katherine Bowman +3 more
openalex +2 more sources
Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A. [PDF]
Dutta A +5 more
europepmc +1 more source
Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A? [PDF]
Sidonio RF +5 more
europepmc +1 more source
Thoracoscopic lobectomy in a lung cancer patient with severe hemophilia: A case report
XING-YU LIN +5 more
openalex +2 more sources

